martedì, 18 agosto 2026

Notizie AIOM – anno XV n. 651

14 Novembre 2017

Bevacizumab Biosimilar Nears European Approval

November 10, 2017 - The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of the bevacizumab biosimilar ABP 215 for the treatment of patients across several tumor types. The positive opinion will now be reviewed by ...
Leggi tutto

13 Novembre 2017

FDA Approves Dasatinib for Pediatric Ph+ Chronic Phase CML

November 10, 2017 - The FDA has approved dasatinib for the treatment of pediatric patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP). The approval is based on results with dasatinib demonstrated in 97 pediatric patients ...
Leggi tutto

13 Novembre 2017

10 novembre 2017 – Vaccinazione antinfluenzale: che cos’è e perché è importante

13 Novembre 2017

10 novembre 2017 – Melazzini al primo incontro dell’Alleanza Italiana Malattie Rare

10 Novembre 2017

FDA Approves Brentuximab Vedotin for Primary Cutaneous Anaplastic Large Cell Lymphoma

November 9, 2017 - Today, the U.S. Food and Drug Administration (FDA) granted regular approval to brentuximab vedotin for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides who have received ...
Leggi tutto

10 Novembre 2017

10 novembre 2017 – FDA approva il primo trattamento per la malattia di Erdheim-Chester

10 Novembre 2017

FDA Approves Letermovir for Prophylaxis of Cytomegalovirus Infection and Disease in Allogeneic Stem Cell Transplant Patients

November 9, 2017 - Today, the U.S. Food and Drug Administration (FDA) approved letermovir once-daily tablets for oral use and injection for intravenous infusion. Letermovir is indicated for prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive ...
Leggi tutto

9 Novembre 2017

Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

Immune checkpoint inhibitors (ICI) targeting the PD-1/PD-L1 axis induce sustained clinical responses in a sizeable minority of cancer patients. Here, we show that primary resistance to ICI can be due to abnormal gut microbiome composition. Antibiotics (ATB) inhibited the ...
Leggi tutto

9 Novembre 2017

Characterization of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program

Male breast cancer (BC) is rare, managed by extrapolation from female BC. The International Male BC Program aims to better characterize and manage this disease. We report the results of part 1, a retrospective-joint-analysis of cases diagnosed during a 20-year-period. Patients ...
Leggi tutto

9 Novembre 2017

Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer

Opioid-induced constipation (OIC) is a frequent and debilitating adverse effect (AE) of opioids-common analgesics for cancer pain. We investigated the efficacy and safety of a peripherally acting μ-opioid receptor antagonist, naldemedine (S-297995), for OIC, specifically ...
Leggi tutto